Yes, Ibrance (palbociclib) is commonly used in combination with Femara (letrozole) for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women.
Yes, Ibrance (palbociclib) is commonly used in combination with Femara (letrozole) for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women.